IBRN vs. CNCR

Last updated Jun 3, 2026

IBRN (iShares Neuroscience and Healthcare ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - IBRN tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. IBRN charges 0.47%/yr vs 0.79%/yr for CNCR.

Performance

IBRN vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Neuroscience and Healthcare ETF (IBRN) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

IBRN

• 1D: -4.52%
• 1M: -1.90%
• YTD: 4.62%
• 6M: 12.73%
• 1Y: 52.57%
• 3Y*: 11.10%
• 5Y*: —
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IBRN vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
IBRN iShares Neuroscience and Healthcare ETF	4.40%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

IBRN vs. CNCR - Sectors Allocation Comparison

Sectors	IBRN	CNCR
Healthcare	100.0%	96.6%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

IBRN vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IBRN

IBRN Risk / Return Rank: 69
IBRN Sharpe Ratio Rank: 61
IBRN Sortino Ratio Rank: 62
IBRN Omega Ratio Rank: 53
IBRN Calmar Ratio Rank: 92
IBRN Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IBRN vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Neuroscience and Healthcare ETF (IBRN) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IBRN	CNCR	Difference
Sharpe ratio Return per unit of total volatility	2.09	—	—
Sortino ratio Return per unit of downside risk	2.94	—	—
Omega ratio Gain probability vs. loss probability	1.34	—	—
Calmar ratio Return relative to maximum drawdown	6.30	—	—
Martin ratio Return relative to average drawdown	15.59	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	IBRN	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.09	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.37	—	—

Drawdowns

IBRN vs. CNCR - Drawdown Comparison

The maximum IBRN drawdown since its inception was -35.38%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for IBRN and CNCR.

Drawdown Indicators

	IBRN	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-35.38%	0.00%	-35.38%
Max Drawdown (1Y) Largest decline over 1 year	-8.80%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-35.38%	—	—
Current Drawdown Current decline from peak	-6.28%	0.00%	-6.28%
Average Drawdown Average peak-to-trough decline	-9.83%	0.00%	-9.83%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.56%	—	—

Volatility

Volatility by Period

	IBRN	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.66%	—	—
Volatility (6M) Calculated over the trailing 6-month period	19.29%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	25.38%	0.00%	+25.38%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.32%	0.00%	+25.32%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.32%	0.00%	+25.32%

IBRN vs. CNCR - Expense Ratio Comparison

IBRN has a 0.47% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

IBRN vs. CNCR - Dividend Comparison

IBRN's dividend yield for the trailing twelve months is around 0.95%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%
IBRN iShares Neuroscience and Healthcare ETF	0.95%	0.99%	0.40%	0.06%

Frequently Asked Questions

Which ETF is better, IBRN or CNCR?

On fees, IBRN is cheaper at 0.47% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, IBRN or CNCR?

IBRN is cheaper with a 0.47% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, IBRN or CNCR?

IBRN has the higher dividend yield at 0.95%, compared with 0.00% for CNCR.

What is the main difference between IBRN and CNCR?

IBRN tracks NYSE FactSet Global Neuro Biopharma and MedTech Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: iShares and Exchange Traded Concepts. Their fees differ too: 0.47% for IBRN and 0.79% for CNCR.